QEEG Clinical Report

BrainLens V0.4

Report Description

Personal & Clinical Data

Name	Alishakibayi	Date of Recording	2025-09-02
Date of Birth - Age	1993-01-04 - 32.8	Gender	Male
Handedness(R/L)	Right	Source of Referral	Mr Karami
Initial Diagnosis	Adult ADHD-Aggressive-Drug Abuse-Mood Swing		
Current Medication	-		

Mr Karami

Summary Report

EEG Quality



Z-score Information



Compatibility with Depression



Compatibility with Mood Swing



Compatibility with Anxiety



Arousal Level



TMS Responsibility



Cognitive Performance



APF

Posterior APF-EC= 11.75

To investigate QEEG-based predicting medication response, please refer to the Report.

Alishakibayi\Mr Karami

Denoising Information (EC)

Raw EEG



Denoised EEG



Flat Channels

Rejected Channels

Number of Eye and Muscle Elements				Low Artifact Percentage	
Eye	0	**Muscle**	0		
Total Artifact Percentage				**High Artifact Percentage**	
EEG Quality	bad			**Total Recording Time Remaining**	48.98 sec

Alishakibayi\Mr Karami

Pathological assessment for mood disorders and adult ADHD

Compare to Mood Disorders Database



Compare to Adult ADHD Database



EEG Compatibility with Depression Diagnosis





EEG Compatibility with Anxiety Diagnosis





EEG Compatibility with Mood Swing Diagnosis *





* This index can only be investigated if there are symptoms of mood swings (R/O BMD or R/O mood swings).

Depression and Adult ADHD Diagnosis Probabiliy



Cognitive Functions Asessment



Arousal Level Detection



Alishakibayi\Mr Karami

Pathological Assessment for Substance Abuse

Relapse Index



Comorbid Symptoms



The relapse graph shows the relapse index based on a combination of EEG neuromarkers. If the type of substance your patient uses is included in this chart, you can read its relapse rate. **The condition for using this chart is that the patient consumes each substance specified in the chart.** If your patient does not consume each of the substances specified in the chart, the index shown is not valid.

Subsance Abuse Compatibiliy





The compatibility graph shows the compatibility of the patient's EEG neuromarkers and the alternations that the specific substance causes in the EEG. In other words, this chart indicates that your patient has how percentage of validated neuromarkers due to the use of specific substances.

Using this chart, you can figure out how substances have affected EEG and if multiple drugs were used, which one has the most dominant effect. **If your patient does not consume each of the substances specified in the chart, the index shown is not valid.**

Functional Problems Source Detection

Eyes Closed

Freq = 11.5 Hz







, NOT Found *,*

Freq = 17.5 Hz







Brodmann area 45
Inferior Frontal Gyrus

Alishakibayi\Mr Karami

rTMS Response Prediction

Network Performance

Accuracy: 92.1%
Sensitivity: 89.13%
Specificity: 97.47%

Participants Information







Features Information



Responsibility



Data Distribution



About Predicting rTMS Response

This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.

Alishakibayi\Mr Karami

Alpha Asymmetry(AA)



APF(EC)



Frontal APF= 11.33

Posterior APF= 11.75

Absolute Power-Eye Closed (EC)



Relative Power-Eye Closed (EC)



Alishakibayi\Mr Karami

Z Score Summary Information (EC)



E.C.T/B Ratio (Raw- Z Score)





Arousal Level





EEG Spectra